Литература
1. Liu R., Chen C., Xia X. et al. Homozygous p.Ser267/Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine // Sci. Rep. 2017. Vol. 7, N 1. P. 9214.
2. Klebanov N. Genetic Predisposition to Infectious Disease // Cureus. 2018. Vol. 10, N 8. Article ID e3210.
3. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. 2009. Vol. 461, N 7262. P. 399-401.
4. Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy // Nat. Genet. 2009. Vol. 41, N 10. P. 1100-1174.
5. Tanaka Y., Nishida N., Suqiyama M. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C // Nat. Genet. 2009. Vol. 41, N 10. P. 1105-1109.
6. Thomas D.L., Thio C.L., Martin M.P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus // Nature. 2009. Vol. 461, N 7265. P. 798-801.
7. Rauch A., Kutalik Z., Dercombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study // Gastroenterology. 2010. Vol. 138, N 4. P. 13381345.
8. Малов И.В., Бааратхуу О., Огарков О.Б. и др. Особенности полиморфизма генов интерферона III типа у больных вирусным гепатитом С на сопредельных территориях России и Монголии // Журн. инфекто-логии. 2017. № 3. С. 46-53.
9. Wietzke-Braun P., Maouzi A.B., Manhardt L.B. et al. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection // Eur. J. Gastroenterol. Hepatol. 2006. Vol. 18, N 9. P. 991-997.
10. Askar E., Bregadze R., Mertens J. et al. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C // J. Med. Virol. 2009. Vol. 81, N 7. P. 1204-1211.
11. Kotha S., Neong S., Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma // Expert Rev. Mol. Diagn. 2018. Vol. 18, N 8. P. 713-722.
12. Blach S., Zeuzem S., Manns M. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study // Lancet Gastroenterol. Hepatol. 2017. Vol. 2, N 3. P. 161176.
13. Ashtari S., Pourhoseingholi M.A., Sharifian A., Zali M.R. Hepatocellular carcinoma in Asia: prevention strategy and planning // World J. Hepatol. 2015. Vol. 7, N 12. P. 1708-1717.
14. URL: http://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list. (date of access: November 28, 2018)
15. Чуланов В.П., Исаков В.А., Жданов К.В. и др. Промежуточные результаты международного многоцентрового проспективного наблюдательного исследования "MOSAIC" по оценке эпидемиологии, субъективных и экономических исходов лечения хронического вирусного гепатита С // Инфекц. бол. 2018. Т. 16, № 1. С. 5-14.
16. Кручкин Ю.Н. Современная Монголия. Энциклопедический справочник. Улан-Батор, 2011. 1154 c.
17. Статистический бюллетень. Итоги всероссийской переписи населения 2010 года по Иркутской области. Иркутск : Иркутскстат, 2012. 52 с.
18. Ющук Н.Д. и др. Рекомендации по диагностике и лечению взрослых больных гепатитом С. 3-е изд., испр. и доп. М. : ГЭОТАР-Медиа, 2017. 96 с.
19. European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015 // J. Hepatol. 2015. Vol. 63, N 1. P. 199-236.
20. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma // J. Hepatol. 2018. Vol. 69, N 1. P. 182-236.
21. Санитарно-эпидемиологические правила СП 3.1.3112-13 "Профилактика вирусного гепатита С" (приложение). Постановление от 22 октября 2013 г. № 58. Зарегистрировано в Минюсте России 19 марта 2014 г. № 31646. URL: http://36.rospotrebnadzor.ru/documents/san_nor/14514 (дата обращения: 28.11.2018)
22. Гинзбург В.В. Элементы антропологии для медиков. Л. : Медгиз. 1963. 261 с.
23. General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principal for medical research involving human subject // J. Am. Coll. Dent. 2014. Vol. 81, N. 3. P. 14-18.
24. Babor T., Higgins-Biddle J.C., Saunders J.B., Monteiro M.G. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. 2nd ed. Geneva : World Health Organization, 2001.
25. Савилов Е.Д., Астафьев В.А., Жданова С.Н., Заруднев Е.А. Эпидемиологический анализ: Методы статистической обработки материала. Новосибирск : Наука-Центр. 2011. 156 с.
26. Никитина Г.Ю., Семененко Т.А., Готвянская Т.П. и др. Частота выявления маркеров инфицирования вирусами парентеральных гепатитов среди медицинских работников в регионах Российской Федерации с различной интенсивностью эпидемического процесса // Клин. микро-биол. и антимикроб. химиотер. 2017. Т. 19, № 2. С. 161-167.
27. Gower E., Estes C., Blach S. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection // J. Hepatol. 2014. Vol. 61, N 1. Suppl. P. S45-S57.
28. Qian F., Bolen C.R., Jing C. et al. Impaired toll-like receptor 3-me-diated immune responses from macrophages of patients chronically infected with hepatitis C virus // Clin. Vaccine Immunol. 2013. Vol. 20, N 2. P. 146-155.
29. Тулгаа Л. Гигиеническая оценка факторов риска жирового гепатоза и его клинико-диагностические особенности : автореф. дис. ... канд. мед. наук. Улан-Батор, 2006.
30. Lingala S., Ghany M.G. Natural history of hepatitis C // Gastroenterol. Clin. North Am. 2015. Vol. 44, N 4. P. 717-734.
31. Chan S.T., Ou J.J. Hepatitis C virus-induced autophagy and host innate immune response // Viruses. 2017. Vol. 9, N 8. pii: E224.
32. Rawla P., Sunkara T., Muralidharan P., Raj J.P. Update in global trends and aetiology of hepatocellular carcinoma // Contemp. Oncol. (Pozn.). 2018. Vol. 22, N 3. P. 141-150.
33. Tsatsralt-Od B., Takahashi M., Nishizawa T. et al. High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia // Arch. Virol. 2005. Vol. 150, N 12. P 2513-2528.
34. Бредер В.В., Косырев В.Ю., Кудашкин Н.Е., Лактионов К.К. Ге-патоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема // Мед. совет. 2016. № 10. С. 10-18.
35. Trad D., Bibani N., Sabbah M. et al. Known new and emerging risk factors of hepatocellular carcinoma (review) // Presse Med. 2017. Vol. 46, N 11. P. 1000-1007.
36. Ognjanovic S., Yuan J.M., Chaptmann A.K. et al. Genetic polymorphism in the cytokine genes and risk of hepatocellular carcinoma in low-risk non Asians of USA // Carcinogenesis. 2009. Vol. 30, N 5. P. 758-762.
37. Ngamruengphong S., Patel T. Molecular evolution of genetic susceptibility to hepatocellular carcinoma // Dig. Dis. Sci. 2014. Vol. 59, N 5. P. 986-991.
38. Cole P., Morrison A.S. Basic issues in population screening for cancer // J. Natl Cancer Inst. 1980. Vol. 64, N 5. P 1263-1272.
References
1. Liu R., Chen C., Xia X., et al. Homozygous p.Ser267/Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicine. Sci Rep. 2017; 7 (1): 9214.
2. Klebanov N. Genetic predisposition to infectious disease. Cureus. 2018; 10 (8): e3210.
3. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461 (7262): 399-401.
4. Suppiah V., Moldovan M., Ahlenstiel G., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41 (10): 1100-74.
5. Tanaka Y., Nishida N., Suqiyama M., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41 (10): 1105-9.
6. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461 (7265): 798-801.
7. Rauch A., Kutalik Z., Dercombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138 (4): 1338-45.
8. Malov I.V., Baatarkhuu O., Ogarkov O.B., et al. Peculiarities of the III type interferon genes’ polymorphism in HCV patients on the cross-border regions of Russia and Mongolia. Zhurnal infektologii [Journal of Infectology]. 2017; 9 (3): 46-53. (in Russian)
9. Wietzke-Braun P, Maouzi A.B., Manhardt L.B., et al. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur J Gastroenterol. Hepatol. 2006; 18 (9): 991-7.
10. Askar E., Bregadze R., Mertens J., et al. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J Med Virol. 2009; 81 (7): 1204-11.
11. Kotha S., Neong S., Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn. 2018; 18 (8): 713-22.
12. Blach S., Zeuzem S., Manns M., et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017; 2 (3): 161-76.
13. Ashtari S., Pourhoseingholi M.A., Sharifian A., Zali M.R. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol. 2015; 7 (12): 1708-17.
14. URL: http://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list (date of access: November 28, 2018)
15. Chulanov V.P., Isakov V.A., Zhdanov K.V., et al. Interim results of the International Multicenter Prospective Observational Study to Evaluate the Epidemiology, HumAnistic and Economic Outcomes of Treatment for Chronic Hepatitis С Virus (HCV) (MOSAIC). Infektsionnye bolezni [Infectious Diseases]. 2018; 16 (1): 5-14. (in Russian)
16. Kruchkin Yu.N. Modern Mongolia: Encyclopedic reference book. Ulan-Bator, 2011: 1154 p. (in Russian)
17. Statistical Bulletin. The results of the all-Russian census of 2010 in the Irkutsk region. Irkutsk: Irkutskstat; 2012: 52 p. (in Russian)
18. Yushchuk N.D., et al. Recommendations on diagnostics and treatment of adult hepatitis C patients. Moscow: GEOTAR-Media, 2017: 96 p. (in Russian)
19. European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015; 63 (1): 199-236.
20. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69 (1): 182-236.
21. Sanitary-epidemiology rules SP "Prevention of viral hepatitis C" (attachment). Decree of October 22, 2013. No. 58. Registered with the Russian Ministry of Justice March 19, 2014. No. 31646. URL: http://36.rospotrebnadzor.ru/documents/san_nor/14514 (28.11.2018). (in Russian)
22. Ginzburg V.V. Elements of anthropology for physicians. Leningrad: Medgiz, 1963: 261 p. (in Russian)
23. General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principal for medical research involving human subject. J Am Coll Dent. 2014; 81 (3): 14-8.
24. Babor T., Higgins-Biddle J.C., Saunders J.B., Monteiro M.G. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. 2nd ed. Geneva: World Health Organization, 2001.
25. Savilov E.D., Astaf'ev V.A., Zhdanova S.N., Zarudnev E.A. Epidemiological analysis: methods of statistical processing of the material. Novosibirsk: Science Center, 2011: 156 p. (in Russian)
26. Nikitina G.Yu., Semenenko T.A., Gotvyanskaya T.P., et al. The prevalence of parenteral hepatitis markers among the medical personnel in the Russian Federation regions with different intensity of epidemic process. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya [Clinical Microbiology and Antimicrobial Chemotherapy]. 2017; 19 (2): 161-7. (in Russian)
27. Gower E., Estes C., Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61 (1): S45-57.
28. Qian F., Bolen C.R., Jing C., et al. Impaired toll-like receptor 3-medi-ated immune responses from macrophages of patients chronically infected with hepatitis C virus. Clin Vaccine Immunol. 2013; 20 (2): 146-55.
29. Tulgaa L. Hygienic assessment of risk factors for fatty hepatosis and its clinical and diagnostic features: Autoabstract of Diss. Ulan-Bator, 2006. (in Russian)
30. Lingala S., Ghany M.G. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015; 44 (4): 717-34.
31. Chan S.T., Ou J.J. Hepatitis C virus-induced autophagy and host innate immune response. Viruses. 2017; 9 (8): pii: E224.
32. Rawla P, Sunkara T., Muralidharan P, Raj J.P. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018; 22 (3): 141-50.
33. Tsatsralt-Od B., Takahashi M., Nishizawa T., et al. High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia. Arch Virol. 2005; 150 (12): 2513-28.
34. Breder V.V., Kosyrev V.Y., Kudashkin N.E., Laktionov K.K. Hepatocellular carcinoma as a social and medical problem in the Russian Federation. Meditsinskiy sovet [Medical Council]. 2016; (10): 10-8. (in Russian)
35. Trad D., Bibani N., Sabbah M., et al. Known new and emerging risk factors of hepatocellular carcinoma (review). Presse Med. 2017; 46 (11): 1000-7.
36. Ognjanovic S., Yuan J.M., Chaptmann A.K., et al. Genetic polymorphism in the cytokine genes and risk of hepatocellular carcinoma in low-risk non Asians of USA. Carcinogenesis. 2009. 30 (5): 758-62.
37. Ngamruengphong S., Patel T. Molecular evolution of genetic susceptibility to hepatocellular carcinoma. Dig Dis Sci. 2014; 59 (5): 986-91.
38. Cole P., Morrison A.S. Basic issues in population screening for cancer. J Natl Cancer Inst. 1980; 64 (5): 1263-72.